Testosterone/bicalutamide antagonism at the predicted extracellular androgen binding site of ZIP9

Publication date: December 2017 Source:Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Volume 1864, Issue 12 Author(s): Ahmed Bulldan, Viveka Nand Malviya, Neha Upmanyu, Lutz Konrad, Georgios Scheiner-Bobis ZIP9 is a Zn2+ transporter, testosterone receptor, and mediator of signaling events through G-proteins. Despite these pivotal properties, however, its physiological and pathophysiological significance has not yet been comprehensively addressed. Using a cell line that lacks the classical androgen receptor we show that ZIP9-mediated phosphorylation of Erk1/2, CREB, or ATF-1 and expression of claudin-5 and zonula occludens-1 by testosterone can be completely antagonized by bicalutamide (Casodex), an anti-androgen of significant clinical impact. Computational modeling and docking experiments with ZIP9 reveal typical characteristics of ZIP transporters and an extracellular binding site for testosterone capable of accommodating bicalutamide. The presence of this site is verified by our demonstration that the membrane-impermeable testosterone analogue T-BSA-FITC labels the membrane only when ZIP9 is expressed and that this labeling is completely prevented by bicalutamide. The study connects structural features of ZIP9 to its functions and indicates a possible relevance of ZIP9 as a pharmacological target.

Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - October 4, 2017 Category: Molecular Biology Source Type: research